Finland· FI-REL-REL34984

Votrient

A pazopanib product containing pazopanib hydrochloride, registered in Finland by Novartis Europharm Limited. The same ATC class is registered in 14 of our 19 countries.

ATC L01EX03

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedVotrientATCL01EX03REGISTER NO.FI-REL-REL34984PACKS LISTED1CHECKEDSeptember 27, 2026

Where it is registered

Pazopanib is registered in 14 of 19 countries.

Countries holding a registration under ATC L01EX03 (pazopanib), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 8 of them publish a price we can compare per daily dose

Pazopanib · ATC L01EX03

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of pazopanib costs, country by country.

Normalised to the WHO defined daily dose (0.8 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Pazopanib · price per daily dose (0.8 g)

USD · FX 28 Sept 2026

  • CH Switzerland$87.69
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Fimea (Finland)
Active substance
Pazopanib hydrochloride
Manufacturer
Novartis Europharm Limited
Country
Finland (FI)
ATC code
L01EX03
ATC class
Pazopanib
Defined daily dose
0.8 g, O
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 1

1 priced
  • fi_myyntilupa
    085366
    90
    EUR 841.67

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

593 interactions on record for pazopanib.

Graded by severity as the source publishes them — 155 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Pazopanib · interactions on record

593 records

  • 155 severe
  • 428 moderate
  • 10 minor

Most severe, free to view

  • CimetidineA02BA01severe
  • RanitidineA02BA02severe
  • FamotidineA02BA03severe
  • NizatidineA02BA04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Pazopanib in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All pazopanib products

Authorised across Europe · EMA

The same active substance is authorised in 30 EEA countries. Names it is sold under:

  • Austria · Pazopanib Devatis
  • Belgium · Pazopanib Accord, Pazopanib Eg
  • Bulgaria · Алуниб, Пазопаниб G.L. Pharma
  • Cyprus · Pazopanib Sapiens, Pazorem
  • Czechia · Pazopanib Accord, Pazopanib Sandoz
  • Germany · Pazopanib Al, Pazopanib Beta
  • Denmark · Pazopanib Accord, Pazopanib Glenmark
  • Estonia · Pazopanib Accord, Pazopanib Teva
  • Spain · Pazopanib Accord, Pazopanib Dr. Reddys
  • France · Pazopanib Accord, Pazopanib Biogaran
  • United Kingdom (Northern Ireland) · Pazopanib Accord, Pazopanib Accord Healthcare
  • Greece · Pazopanib Accord, Pazopanib Stada
  • Croatia · Pazopanib Accord, Pazopanib Frontier
  • Hungary · Pazopanib Accord, Pazopanib G.L. Pharma
  • Ireland · Pazopanib Accord, Pazopanib Reddy
  • Iceland · Pazopanib Adalvo, Pazopanib Stada
  • Italy · Pazopanib Accord, Pazopanib Dr. Reddy’s
  • Liechtenstein · Votrient
  • Lithuania · Pazopanib Accord, Pazopanib Auxilia
  • Luxembourg · Pazopanib Eg, Pazopanib Pazopanib Eg
  • Latvia · Pazopanib Accord, Pazopanib Teva
  • Malta · Pazopanib Pharmacare, Pazopanib Pharos
  • Netherlands · Pazopanib Accord, Pazopanib Cf
  • Norway · Pazopanib Accord, Pazopanib Glenmark
  • Poland · Pazopanib Accord, Pazopanib Glenmark
  • Portugal · Pazopanib Accord, Pazopanib Bluepharma
  • Romania · Pazopanib Accord, Pazopanib Dr. Reddys
  • Sweden · Pazopanib Accord, Pazopanib Glenmark
  • Slovenia · Pazopanib Accord, Pazopanib Teva
  • Slovakia · Pazopanib Accord, Pazopanib G.L. Pharma

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/a97f1e3f-5b87-4287-a1e7-75ce470af37c
GET /v1/drugs/a97f1e3f-5b87-4287-a1e7-75ce470af37c?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": "0.8",
  "form": "tabletti, kalvopäällysteinen",
  "route": "Suun kautta",
  "ddd_unit": "g",
  "strength": "200 mg",
  "atc_label": "patsopanibi",
  "ma_number": null,
  "auth_status": "Myyntilupa myönnetty",
  "eu_ma_number": "EU/1/10/628/001-002",
  "fimea_rel_id": "REL34984",
  "authorised_at": "2010-06-14"
}

See everything about pazopanib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.